Prolonged Overall Survival For Patients With Acute Myeloid Leukemia Demonstrated By Data

The Myelodysplastic Syndromes (MDS) Foundation have announced that data presented at this year’s American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).

More: continued here

Filed under: Clinical Trials on December 11th, 2008